UROV - Urovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.51
-0.49 (-8.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.00
Open5.88
Bid0.00 x 800
Ask14.32 x 1400
Day's Range5.51 - 6.01
52 Week Range5.51 - 14.32
Volume20,436
Avg. Volume150,480
Market Cap167.079M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.67
Trade prices are not sourced from all markets
  • Business Wire29 days ago

    Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference

    Urovant Sciences , a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A.

  • Business Wirelast month

    Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update

    Urovant Sciences Ltd. , a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates.

  • Business Wirelast month

    Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder

    Urovant Sciences (UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced it completed enrollment in its international Phase 3 clinical trial, EMPOWUR, evaluating the safety and efficacy of vibegron as a treatment for adults with symptoms of overactive bladder. “I am proud of the progress made since initiating our robust EMPOWUR clinical trial in March of 2018,” said Dr. Cornelia Haag-Molkenteller, Chief Medical Officer of Urovant. EMPOWUR is a randomized, double-blind placebo- and active comparator controlled clinical trial in men and women with symptoms of overactive bladder, including frequent urination, sudden urge to urinate, and urge incontinence or leakage.

  • Business Wirelast month

    Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results

    Urovant Sciences Ltd. , a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced it will report 2018 second fiscal quarter financial results after the close of U.S.

  • Business Wire2 months ago

    Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology

    Urovant Sciences (UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced the publication of positive results from the international Phase 2b study of vibegron, an investigational oral beta-3 adrenergic agonist being studied for adults with symptoms of overactive bladder (OAB). The study, which demonstrated once-daily vibegron was well-tolerated and improved OAB symptoms, was published online by European Urology, a peer-reviewed medical journal and official journal of the European Association of Urology. The international, randomized double-blind, placebo-controlled Phase 2b study including an active comparator enrolled more than 1,300 patients with OAB symptoms including frequent urination, sudden urge to urinate, and urge incontinence (leakage).

  • GuruFocus.com2 months ago

    Andreas Halvorsen Discloses Stake in Urovant Sciences

    Halvorsen's Viking made one of the largest-ever private biotech investments in its parent company

  • The Wall Street Journal3 months ago

    [$$] Gormley's Take: Urovant Sciences IPO Draws Attention to Urology Market

    went public on Thursday in a deal that highlights a large market that has drawn little venture investment until recently. The company, a spinoff of SoftBank-backed Roivant Sciences, is developing a drug to treat an overactive bladder, a condition that affects millions of Americans and is a serious public-health burden, according to a 2016 study published in the journal Current Bladder Dysfunction Reports. In recent years the number of venture rounds completed in urology each year has typically been in the single digits, according to Dow Jones VentureSource.

  • PR Newswire3 months ago

    Urovant Sciences Ltd. Announces Pricing of Initial Public Offering

    BASEL, Switzerland and IRVINE, Calif. , Sept. 26, 2018 /PRNewswire/ -- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, ...

  • Benzinga3 months ago

    The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...